Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Rochelle P. Walensky, M.D.

Co-Author

This page shows the publications co-authored by Rochelle Walensky and Kenneth Freedberg.
Connection Strength

19.436
  1. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India. AIDS Res Hum Retroviruses. 2018 06; 34(6):486-497.
    View in: PubMed
    Score: 0.779
  2. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2014 02 06; 370(6):581-2.
    View in: PubMed
    Score: 0.581
  3. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31; 369(18):1715-25.
    View in: PubMed
    Score: 0.570
  4. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis. 2010 Jul 01; 51(1):85-92.
    View in: PubMed
    Score: 0.453
  5. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS. 2007 Jul; 21 Suppl 4:S117-28.
    View in: PubMed
    Score: 0.368
  6. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006 Jul 01; 194(1):11-9.
    View in: PubMed
    Score: 0.341
  7. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Public Health. 2005 Jan; 95(1):71-3.
    View in: PubMed
    Score: 0.309
  8. A therapeutic HIV vaccine: how good is good enough? Vaccine. 2004 Sep 28; 22(29-30):4044-53.
    View in: PubMed
    Score: 0.304
  9. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. . 2002 Sep 01; 31(1):27-37.
    View in: PubMed
    Score: 0.263
  10. AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States. Clin Infect Dis. 2002 Sep 01; 35(5):606-10.
    View in: PubMed
    Score: 0.262
  11. Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med. 2002 Apr 22; 162(8):887-92.
    View in: PubMed
    Score: 0.257
  12. Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. Clin Infect Dis. 2021 10 05; 73(7):e2077-e2085.
    View in: PubMed
    Score: 0.247
  13. Investigation of primary human immunodeficiency virus infection in patients who test positive for heterophile antibody. Clin Infect Dis. 2001 Aug 15; 33(4):570-2.
    View in: PubMed
    Score: 0.243
  14. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis. Ann Intern Med. 2020 09 15; 173(6):507-508.
    View in: PubMed
    Score: 0.230
  15. A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. J Biomed Inform. 2020 07; 107:103475.
    View in: PubMed
    Score: 0.225
  16. Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. BMJ Open. 2020 05 12; 10(5):e032579.
    View in: PubMed
    Score: 0.224
  17. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States. Clin Infect Dis. 2020 03 17; 70(7):1353-1363.
    View in: PubMed
    Score: 0.222
  18. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Ann Intern Med. 2020 05 05; 172(9):583-590.
    View in: PubMed
    Score: 0.222
  19. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. Clin Infect Dis. 2020 02 03; 70(4):633-642.
    View in: PubMed
    Score: 0.220
  20. Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis. Ann Am Thorac Soc. 2020 02; 17(2):202-211.
    View in: PubMed
    Score: 0.220
  21. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):148-156.
    View in: PubMed
    Score: 0.220
  22. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis. PLoS One. 2019; 14(6):e0219068.
    View in: PubMed
    Score: 0.211
  23. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study. Ann Intern Med. 2019 05 07; 170(9):614-625.
    View in: PubMed
    Score: 0.208
  24. Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. Lancet Glob Health. 2019 02; 7(2):e200-e208.
    View in: PubMed
    Score: 0.205
  25. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. J Int AIDS Soc. 2018 03; 21(3):e25085.
    View in: PubMed
    Score: 0.193
  26. Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Intern Med. 2017 11 01; 177(11):1613-1621.
    View in: PubMed
    Score: 0.188
  27. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. J Infect Dis. 2017 10 17; 216(7):798-807.
    View in: PubMed
    Score: 0.188
  28. Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2017 10 15; 65(8):1266-1271.
    View in: PubMed
    Score: 0.188
  29. The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations. AIDS. 2017 09 24; 31(15):2135-2145.
    View in: PubMed
    Score: 0.187
  30. Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Ann Intern Med. 2017 Nov 07; 167(9):618-629.
    View in: PubMed
    Score: 0.186
  31. The value of point-of-Care CD4 and Laboratory viral Load in tailoring ART monitoring Strategies to resource limitations. AIDS. 2017 Jul 07.
    View in: PubMed
    Score: 0.184
  32. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infect Dis. 2017; 4(2):ofx081.
    View in: PubMed
    Score: 0.181
  33. Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. J Infect Dis. 2016 Dec 01; 214(11):1672-1681.
    View in: PubMed
    Score: 0.176
  34. The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. Ann Intern Med. 2016 09 06; 165(5):325-33.
    View in: PubMed
    Score: 0.171
  35. Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. J Int AIDS Soc. 2016; 19(1):20623.
    View in: PubMed
    Score: 0.169
  36. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clin Infect Dis. 2016 06 01; 62(11):1454-1462.
    View in: PubMed
    Score: 0.168
  37. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. J Infect Dis. 2016 May 15; 213(10):1523-31.
    View in: PubMed
    Score: 0.165
  38. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Clin Trials. 2015 Nov; 16(6):207-18.
    View in: PubMed
    Score: 0.165
  39. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clin Infect Dis. 2016 Mar 15; 62(6):784-91.
    View in: PubMed
    Score: 0.165
  40. The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. J Virus Erad. 2015; 1(4):245-249.
    View in: PubMed
    Score: 0.163
  41. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS. 2015 Jun 19; 29(10):1247-59.
    View in: PubMed
    Score: 0.160
  42. Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis. PLoS One. 2015; 10(3):e0117751.
    View in: PubMed
    Score: 0.157
  43. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One. 2014; 9(11):e113031.
    View in: PubMed
    Score: 0.153
  44. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis. PLoS Med. 2014 Sep; 11(9):e1001725.
    View in: PubMed
    Score: 0.152
  45. The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials. HIV Clin Trials. 2014 Sep-Oct; 15(5):185-98.
    View in: PubMed
    Score: 0.151
  46. Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival. AIDS. 2014 Jul; 28 Suppl 3:S287-99.
    View in: PubMed
    Score: 0.149
  47. Misinterpretation of HIV preexposure prophylaxis findings. Clin Infect Dis. 2014 Jul 01; 59(1):139-41.
    View in: PubMed
    Score: 0.147
  48. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One. 2014; 9(1):e85197.
    View in: PubMed
    Score: 0.145
  49. Validation and calibration of a computer simulation model of pediatric HIV infection. PLoS One. 2013; 8(12):e83389.
    View in: PubMed
    Score: 0.144
  50. The survival benefits of antiretroviral therapy in South Africa. J Infect Dis. 2014 Feb 15; 209(4):491-9.
    View in: PubMed
    Score: 0.144
  51. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. PLoS One. 2013; 8(5):e64604.
    View in: PubMed
    Score: 0.139
  52. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013 Jan 15; 158(2):84-92.
    View in: PubMed
    Score: 0.135
  53. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis. 2013 Feb; 56(3):430-46.
    View in: PubMed
    Score: 0.134
  54. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis. 2013 Feb; 56(4):587-97.
    View in: PubMed
    Score: 0.133
  55. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther. 2013; 18(1):45-55.
    View in: PubMed
    Score: 0.130
  56. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012 Jun 01; 26(9):1083-93.
    View in: PubMed
    Score: 0.129
  57. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS. 2012 May 15; 26(8):987-95.
    View in: PubMed
    Score: 0.129
  58. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012; 7(4):e36001.
    View in: PubMed
    Score: 0.128
  59. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012 May; 54(10):1504-13.
    View in: PubMed
    Score: 0.128
  60. Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS. 2012 Mar 13; 26(5):625-34.
    View in: PubMed
    Score: 0.127
  61. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. PLoS Med. 2012 Jan; 9(1):e1001156.
    View in: PubMed
    Score: 0.126
  62. Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med. 2011 Jan; 12(1):46-53.
    View in: PubMed
    Score: 0.117
  63. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr. 2011 Jan 01; 56(1):26-35.
    View in: PubMed
    Score: 0.117
  64. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2010 Dec 21; 7(12):e1000382.
    View in: PubMed
    Score: 0.117
  65. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010 Oct 01; 51(7):823-9.
    View in: PubMed
    Score: 0.115
  66. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010 Aug 15; 51(4):392-400.
    View in: PubMed
    Score: 0.114
  67. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011 Jul; 18(7):506-12.
    View in: PubMed
    Score: 0.113
  68. The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One. 2010 Mar 04; 5(3):e9538.
    View in: PubMed
    Score: 0.111
  69. Frequent HIV testing among participants of a routine HIV testing program. Virulence. 2010 Mar-Apr; 1(2):68-71.
    View in: PubMed
    Score: 0.111
  70. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010 Feb 01; 50(3):416-25.
    View in: PubMed
    Score: 0.110
  71. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009 Nov 15; 49(10):1570-8.
    View in: PubMed
    Score: 0.108
  72. Improving outcomes in state AIDS drug assistance programs. J Acquir Immune Defic Syndr. 2009 Aug 15; 51(5):513-21.
    View in: PubMed
    Score: 0.107
  73. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med. 2009 Aug 04; 151(3):157-66.
    View in: PubMed
    Score: 0.106
  74. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009 Jun 01; 51(2):135-9.
    View in: PubMed
    Score: 0.105
  75. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009 Mar 15; 48(6):806-15.
    View in: PubMed
    Score: 0.103
  76. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS. 2008 Nov 12; 22(17):2359-69.
    View in: PubMed
    Score: 0.101
  77. Late diagnosis of HIV infection at two academic medical centers: 1994-2004. AIDS Care. 2008 Sep; 20(8):977-83.
    View in: PubMed
    Score: 0.100
  78. Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection. HIV Med. 2008 Nov; 9(10):863-7.
    View in: PubMed
    Score: 0.100
  79. Monitoring of antiretroviral therapy in low-resource settings. Lancet. 2008 Jul 26; 372(9635):288; author reply 289.
    View in: PubMed
    Score: 0.099
  80. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis. 2008 May 01; 197(9):1324-32.
    View in: PubMed
    Score: 0.097
  81. Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J. 2008 Mar; 98(3):204-8.
    View in: PubMed
    Score: 0.096
  82. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007 Dec 15; 45 Suppl 4:S248-54.
    View in: PubMed
    Score: 0.095
  83. Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. . 2007 Oct 01; 46(2):181-6.
    View in: PubMed
    Score: 0.094
  84. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8(7):439-50.
    View in: PubMed
    Score: 0.094
  85. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS. 2007 May 11; 21(8):973-82.
    View in: PubMed
    Score: 0.091
  86. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol. 2007 Jan; 143(1):21-8.
    View in: PubMed
    Score: 0.089
  87. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006 Dec 05; 145(11):797-806.
    View in: PubMed
    Score: 0.088
  88. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006 Nov; 44(11):990-7.
    View in: PubMed
    Score: 0.088
  89. Implementing a routine, voluntary HIV testing program in a Massachusetts county prison. J Urban Health. 2006 Nov; 83(6):1127-31.
    View in: PubMed
    Score: 0.088
  90. Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis. 2006 Nov 15; 43(10):1357-64.
    View in: PubMed
    Score: 0.088
  91. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med. 2006 Sep 14; 355(11):1141-53.
    View in: PubMed
    Score: 0.087
  92. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. S Afr Med J. 2006 Jun; 96(6):526-9.
    View in: PubMed
    Score: 0.085
  93. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost. Clin Infect Dis. 2006 Jun 15; 42(12):1772-80.
    View in: PubMed
    Score: 0.085
  94. Assessing the impact of federal HIV prevention spending on HIV testing and awareness. Am J Public Health. 2006 Jun; 96(6):1038-43.
    View in: PubMed
    Score: 0.085
  95. Refusing HIV testing in an urgent care setting: results from the "Think HIV" program. AIDS Patient Care STDS. 2006 Feb; 20(2):84-92.
    View in: PubMed
    Score: 0.083
  96. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005 Nov 01; 41(9):1316-23.
    View in: PubMed
    Score: 0.081
  97. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. . 2005 May 01; 39(1):69-77.
    View in: PubMed
    Score: 0.079
  98. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making. 2005 May-Jun; 25(3):321-9.
    View in: PubMed
    Score: 0.079
  99. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005 Mar; 118(3):292-300.
    View in: PubMed
    Score: 0.078
  100. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med. 2005 Feb 10; 352(6):586-95.
    View in: PubMed
    Score: 0.078
  101. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis. 2004 Aug 01; 39(3):395-401.
    View in: PubMed
    Score: 0.075
  102. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis. 2004 Jun 01; 38(11):1613-22.
    View in: PubMed
    Score: 0.074
  103. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003 Dec 01; 115(8):632-41.
    View in: PubMed
    Score: 0.072
  104. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis. 2003 Mar 01; 36(5):652-62.
    View in: PubMed
    Score: 0.068
  105. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. Clin Infect Dis. 2021 10 05; 73(7):e1927-e1935.
    View in: PubMed
    Score: 0.062
  106. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med. 2001 Aug 15; 111(3):192-4.
    View in: PubMed
    Score: 0.061
  107. Evaluating Point-of-Care Nucleic Acid Tests in Adult Human Immunodeficiency Virus Diagnostic Strategies: A Côte d'Ivoire Modeling Analysis. Open Forum Infect Dis. 2021 Jun; 8(6):ofab225.
    View in: PubMed
    Score: 0.060
  108. Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections. AIDS Behav. 2021 Sep; 25(9):2973-2984.
    View in: PubMed
    Score: 0.059
  109. Strengthening Existing Laboratory-Based Systems vs. Investing in Point-of-Care Assays for Early Infant Diagnosis of HIV: A Model-Based Cost-Effectiveness Analysis. J Acquir Immune Defic Syndr. 2020 07 01; 84 Suppl 1:S12-S21.
    View in: PubMed
    Score: 0.057
  110. Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers. MDM Policy Pract. 2020 Jan-Jun; 5(1):2381468320932894.
    View in: PubMed
    Score: 0.056
  111. Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa. PLoS One. 2019; 14(11):e0225104.
    View in: PubMed
    Score: 0.054
  112. Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus. Open Forum Infect Dis. 2019 Jul; 6(7):ofz276.
    View in: PubMed
    Score: 0.053
  113. Using national laboratory data to assess cumulative frequency of linkage after transfer to community-based HIV clinics in South Africa. J Int AIDS Soc. 2019 06; 22(6):e25326.
    View in: PubMed
    Score: 0.052
  114. Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. Lancet HIV. 2019 03; 6(3):e182-e190.
    View in: PubMed
    Score: 0.051
  115. HIV Testing After a First Positive Rapid Diagnostic Test: A Role for Nucleic Acid Testing? Open Forum Infect Dis. 2018 Aug; 5(8):ofy170.
    View in: PubMed
    Score: 0.050
  116. Optimal breastfeeding durations for HIV-exposed infants: the impact of maternal ART use, infant mortality and replacement feeding risk. J Int AIDS Soc. 2018 04; 21(4):e25107.
    View in: PubMed
    Score: 0.048
  117. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. J Int AIDS Soc. 2018 03; 21(3):e25096.
    View in: PubMed
    Score: 0.048
  118. The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. J Adolesc Health. 2018 01; 62(1):22-28.
    View in: PubMed
    Score: 0.048
  119. The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis. PLoS Med. 2017 Nov; 14(11):e1002446.
    View in: PubMed
    Score: 0.047
  120. Barriers to Care and 1-Year Mortality Among Newly Diagnosed HIV-Infected People in Durban, South Africa. . 2017 04 01; 74(4):432-438.
    View in: PubMed
    Score: 0.045
  121. Adolescent Linkage to Care After a Large-scale Transfer From a Hospital-based HIV Clinic to the Public Sector in South Africa. Pediatr Infect Dis J. 2017 03; 36(3):311-313.
    View in: PubMed
    Score: 0.045
  122. Sizanani: A Randomized Trial of Health System Navigators to Improve Linkage to HIV and TB Care in South Africa. J Acquir Immune Defic Syndr. 2016 Oct 01; 73(2):154-60.
    View in: PubMed
    Score: 0.044
  123. Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency. J Infect Dis. 2016 Nov 01; 214(9):1319-1328.
    View in: PubMed
    Score: 0.043
  124. Finding HIV in hard to reach populations: mobile HIV testing and geospatial mapping in Umlazi township, Durban, South Africa. AIDS Behav. 2015 Oct; 19(10):1888-95.
    View in: PubMed
    Score: 0.041
  125. The lifetime medical cost savings from preventing HIV in the United States. Med Care. 2015 Apr; 53(4):293-301.
    View in: PubMed
    Score: 0.039
  126. Cost-effectiveness of genotype testing for primary resistance in Brazil. . 2015 Feb 01; 68(2):152-61.
    View in: PubMed
    Score: 0.039
  127. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis. 2015 Apr 01; 60(7):1102-10.
    View in: PubMed
    Score: 0.039
  128. HIV testing rates, prevalence, and knowledge among outpatients in Durban, South Africa: Time trends over four years. Int J STD AIDS. 2015 Sep; 26(10):704-9.
    View in: PubMed
    Score: 0.038
  129. Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil. AIDS Res Ther. 2014; 11:29.
    View in: PubMed
    Score: 0.038
  130. The Linkage Outcomes of a Large-scale, Rapid Transfer of HIV-infected Patients From Hospital-based to Community-based Clinics in South Africa. Open Forum Infect Dis. 2014 Sep; 1(2):ofu058.
    View in: PubMed
    Score: 0.038
  131. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2014 Jul 01; 66(3):294-302.
    View in: PubMed
    Score: 0.037
  132. Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa. PLoS One. 2014; 9(5):e98272.
    View in: PubMed
    Score: 0.037
  133. Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study. BMC Infect Dis. 2014 Feb 26; 14:110.
    View in: PubMed
    Score: 0.036
  134. Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PLoS One. 2013; 8(12):e84173.
    View in: PubMed
    Score: 0.036
  135. Linkage to care following community-based mobile HIV testing compared with clinic-based testing in Umlazi Township, Durban, South Africa. HIV Med. 2014 Jul; 15(6):367-72.
    View in: PubMed
    Score: 0.036
  136. Linkage to HIV, TB and non-communicable disease care from a mobile testing unit in Cape Town, South Africa. PLoS One. 2013; 8(11):e80017.
    View in: PubMed
    Score: 0.036
  137. A randomized trial to optimize HIV/TB care in South Africa: design of the Sizanani trial. BMC Infect Dis. 2013 Aug 26; 13:390.
    View in: PubMed
    Score: 0.035
  138. Factors associated with self-reported repeat HIV testing after a negative result in Durban, South Africa. PLoS One. 2013; 8(4):e62362.
    View in: PubMed
    Score: 0.034
  139. Risk factors for late-stage HIV disease presentation at initial HIV diagnosis in Durban, South Africa. PLoS One. 2013; 8(1):e55305.
    View in: PubMed
    Score: 0.034
  140. Depressive symptoms and their impact on health-seeking behaviors in newly-diagnosed HIV-infected patients in Durban, South Africa. AIDS Behav. 2012 Nov; 16(8):2226-35.
    View in: PubMed
    Score: 0.033
  141. Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa. PLoS One. 2012; 7(8):e43281.
    View in: PubMed
    Score: 0.033
  142. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012 Jan 02; 26(1):45-56.
    View in: PubMed
    Score: 0.031
  143. Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. J Acquir Immune Defic Syndr. 2012 Jan 01; 59(1):25-30.
    View in: PubMed
    Score: 0.031
  144. WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. PLoS One. 2011; 6(6):e20224.
    View in: PubMed
    Score: 0.030
  145. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011 May 20; 9:59.
    View in: PubMed
    Score: 0.030
  146. Loss to follow-up in a community clinic in South Africa--roles of gender, pregnancy and CD4 count. S Afr Med J. 2011 Apr; 101(4):253-7.
    View in: PubMed
    Score: 0.030
  147. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS. 2011 Feb 20; 25(4):479-92.
    View in: PubMed
    Score: 0.030
  148. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011 Feb; 12(2):97-108.
    View in: PubMed
    Score: 0.029
  149. Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One. 2010 Oct 01; 5(10):e13132.
    View in: PubMed
    Score: 0.029
  150. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS One. 2010 Sep 16; 5(9).
    View in: PubMed
    Score: 0.029
  151. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):258-68.
    View in: PubMed
    Score: 0.028
  152. CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antivir Ther. 2010; 15(3):351-61.
    View in: PubMed
    Score: 0.027
  153. Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS. 2010 Jan; 24 Suppl 1:S37-44.
    View in: PubMed
    Score: 0.027
  154. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med. 2009 Oct; 6(10):e1000173.
    View in: PubMed
    Score: 0.027
  155. HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr. 2009 Jul 01; 51(3):310-6.
    View in: PubMed
    Score: 0.026
  156. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009; 14(4):523-31.
    View in: PubMed
    Score: 0.026
  157. Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents. HIV Clin Trials. 2009 Jan-Feb; 10(1):13-24.
    View in: PubMed
    Score: 0.026
  158. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008 Oct 01; 22(15):2025-33.
    View in: PubMed
    Score: 0.025
  159. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis. 2007 Apr 15; 44(8):1115-22.
    View in: PubMed
    Score: 0.022
  160. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials. 2006 Mar-Apr; 7(2):59-69.
    View in: PubMed
    Score: 0.021
  161. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS. 2005 Aug 12; 19(12):1299-308.
    View in: PubMed
    Score: 0.020
  162. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther. 2005; 10(1):41-52.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.